Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

BiondVax Pharmaceuticals stock price, quote, forecast and news

BVXV
US09073Q1058
A14TFZ

Price

2.45 ILS
Today +/-
+0 ILS
Today %
+0 %
P

BiondVax Pharmaceuticals stock price

ILS
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the BiondVax Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the BiondVax Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the BiondVax Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze BiondVax Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

BiondVax Pharmaceuticals Stock Price History

DateBiondVax Pharmaceuticals Price
11/7/20232.45 ILS
11/6/20232.61 ILS

BiondVax Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into BiondVax Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BiondVax Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BiondVax Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of BiondVax Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into BiondVax Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing BiondVax Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BiondVax Pharmaceuticals’s growth potential.

BiondVax Pharmaceuticals Revenue, EBIT and net profit per share

DateBiondVax Pharmaceuticals RevenueBiondVax Pharmaceuticals EBITBiondVax Pharmaceuticals Net Income
2026e0 ILS-14.36 M ILS-761,592.9 ILS
2025e0 ILS-16.25 M ILS-532,646.06 ILS
2024e0 ILS-20.4 M ILS-3.8 M ILS
2023e0 ILS-12.84 M ILS-48.45 M ILS
2022e0 ILS-13.67 M ILS-569,962.14 ILS
20210 ILS-9.52 M ILS-10.92 M ILS
20200 ILS7.33 M ILS-4.46 M ILS
20190 ILS-20.47 M ILS-28.53 M ILS
20180 ILS-20.13 M ILS-22.92 M ILS
20170 ILS-6.18 M ILS-9.03 M ILS
20160 ILS-11.9 M ILS-9.18 M ILS
20150 ILS-11.3 M ILS-10.2 M ILS
20140 ILS-8.14 M ILS-7.76 M ILS
20130 ILS-7.64 M ILS-8.04 M ILS
20120 ILS-9.13 M ILS-9.33 M ILS
20110 ILS-8.22 M ILS-7.72 M ILS
20100 ILS-7.54 M ILS-9.27 M ILS
20090 ILS-3.56 M ILS-4.58 M ILS
20080 ILS-3.52 M ILS-3.2 M ILS
20070 ILS-5.49 M ILS-4.84 M ILS

BiondVax Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M ILS)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M ILS)EBIT (M ILS)EBIT MARGIN (%)NET INCOME (M ILS)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2026e
00000000000000000000
--------------------
--------------------
0000-4-200000000000000
-5-3-3-7-8-9-7-8-11-11-6-20-207-9-13-12-20-16-14
--------------------
-4-3-4-9-7-9-8-7-10-9-9-22-28-4-100-48-300
--25.0033.33125.00-22.2228.57-11.11-12.5042.86-10.00-144.4427.27-85.71150.00---93.75--
22.2924.9926.9235.6538.5842.1447.2755.46105.52135.1201.03261.42326.65443.26564.5800000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The BiondVax Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the BiondVax Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M ILS)RECEIVABLES (M ILS)OTHER REC. (k ILS)INVENTORIES (M ILS)OTHER CURRENT LIAB. (k ILS)CURRENT ASSETS (M ILS)TANGIBLE ASSETS (M ILS)LONG-T. INVEST. (M ILS)LONG-T. REC. (M ILS)INTANGIBLE ASSETS (k ILS)GOODWILL (M ILS)OTHER NON-CURRENT ASSETS (M ILS)NON-CURRENT ASSETS (M ILS)TOTAL ASSETS (M ILS)LIABILITIESCOMMON STOCK (M ILS)ADDITIONAL PAID-IN CAPITAL (M ILS)RETAINED EARNINGS (M ILS)OTHER EQUITY (M ILS)UNREAL. GAINS/LOSSES (M ILS)EQUITY (M ILS)LIABILITIES (M ILS)PROVISIONS (M ILS)OTHER SHORT-TERM LIAB. (k ILS)SHORT-TERM DEBTS (M ILS)LONG-TERM DEBT PORTION (k ILS)SHORT-TERM REC. (M ILS)LONG-T. LIAB. (M ILS)DEFERRED TAXES (M ILS)OTHER LIAB. (M ILS)LONG-T. LIABILITIES (M ILS)DEBT (M ILS)TOTAL CAPITAL (M ILS)
2007200820092010201120122013201420152016201720182019202020212022
                               
14.310.730.225.217.615.119.911.635.525.371.475.972.52.4614.1214.08
000001.50000000000
000002000000000000
0000000000000000
000000000000000295
14.310.730.225.217.616.819.911.635.525.371.475.972.52.4614.1214.37
0.90.70.624.23.83.32.621.45.528.242.111.9711.5212.7
002.12222.1222.1000000
0000000000000000
1001001000000000000000
0000000000000000
0.100.10.50.50.60.11.10.30.50.90.70.50.120.120
1.10.82.94.56.76.45.55.74.346.428.942.612.0911.6412.7
15.411.533.129.724.323.225.417.339.829.377.8104.8115.114.5525.7627.07
                               
0000000000000000
18.218.24752.364.568.878.578.5110.7113179.7179.9255.381.04101.39116.08
-2.8-6.9-15-24.2-38.8-46.6-54.5-61.9-77.1-87.4-123.4-211.1-320.3-84.85-95.3-115.84
000000000000000-2.01
0000000000000000
15.411.33228.125.722.22416.633.625.656.3-31.2-65-3.816.1-1.76
0.90.81.92.51.60.41.81.81.71.46.921.818.30.811.680.72
000000.100000000.170.21.62
000005000000000000
000000000000015.7900
0000000000007007007730
0.90.81.92.51.611.81.81.71.46.921.81917.472.662.34
0000000000094.4130.61.5918.0220.08
0000000000000000
0000000.10.16.13.118.620.931.30.320.026.41
0000000.10.16.13.118.6115.3161.91.9118.0426.49
0.90.81.92.51.611.91.97.84.525.5137.1180.919.3820.728.83
16.312.133.930.627.323.225.918.541.430.181.8105.9115.915.5726.7927.07
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of BiondVax Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand BiondVax Pharmaceuticals's financial health and stability.

Assets

BiondVax Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that BiondVax Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of BiondVax Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into BiondVax Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M ILS)DEPRECIATION (k ILS)DEFERRED TAXES (M ILS)CHANGES IN WORKING CAPITAL (M ILS)NON-CASH ITEM (M ILS)PAID INTEREST (M ILS)PAID TAXES (M ILS)NET CASH FLOW FROM OPERATING ACTIVITIES (M ILS)CAPITAL EXPENDITURES (M ILS)CASH FLOW FROM INVESTING ACTIVITIES (M ILS)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M ILS)INTEREST INCOME AND EXPENSES (M ILS)NET DEBT CHANGE (M ILS)NET CHANGE IN EQUITY (M ILS)CASH FLOW FROM FINANCING ACTIVITIES (M ILS)CASH FLOW FROM OTHER FINANCING ACTIVITIES (ILS)TOTAL DIVIDENDS PAID (M ILS)NET CHANGE IN CASH FLOW (M ILS)FREE CASH FLOW (M ILS)SHARE-BASED COMPENSATION (M ILS)
2007200820092010201120122013201420152016201720182019202020212022
-7-4-4-9-7-9-8-7-10-9-34-87-109-1-10-5
0000000000001,000000
0000000000000000
0000-202000217-3-3-20
000000000-1211233-146-2
0000000000000000
0000000000000000
-6-3-3-8-9-7-4-7-10-9-10-57-77-18-6-7
000-1-200000-4-23-7-100
00-2-5-20200-76-23-7-100
00-2-400200-71100000
0000000000000000
000000000008414000
1702544490330610703186
17025444903306184853176
----------------
0000000000000000
10-319-9-7-26-823-17554-3-1611-3
-6.35-3.69-3.47-9.67-12.4-7.32-4.4-7.6-10.3-9.67-14.56-80.92-84.49-20.55-6.51-8.1
0000000000000000

BiondVax Pharmaceuticals stock margins

The BiondVax Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BiondVax Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BiondVax Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the BiondVax Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the BiondVax Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the BiondVax Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the BiondVax Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BiondVax Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BiondVax Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BiondVax Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

BiondVax Pharmaceuticals Margin History

BiondVax Pharmaceuticals Gross marginBiondVax Pharmaceuticals Profit marginBiondVax Pharmaceuticals EBIT marginBiondVax Pharmaceuticals Profit margin
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
2022e0 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %

BiondVax Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The BiondVax Pharmaceuticals earnings per share therefore indicates how much revenue BiondVax Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BiondVax Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BiondVax Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BiondVax Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BiondVax Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BiondVax Pharmaceuticals Revenue, EBIT and net profit per share

DateBiondVax Pharmaceuticals Sales per ShareBiondVax Pharmaceuticals EBIT per shareBiondVax Pharmaceuticals Earnings per Share
2026e0 ILS0 ILS-0.04 ILS
2025e0 ILS0 ILS-0.03 ILS
2024e0 ILS0 ILS-0.2 ILS
2023e0 ILS0 ILS-2.6 ILS
2022e0 ILS0 ILS-0.03 ILS
20210 ILS-0.02 ILS-0.02 ILS
20200 ILS0.02 ILS-0.01 ILS
20190 ILS-0.06 ILS-0.09 ILS
20180 ILS-0.08 ILS-0.09 ILS
20170 ILS-0.03 ILS-0.04 ILS
20160 ILS-0.09 ILS-0.07 ILS
20150 ILS-0.11 ILS-0.1 ILS
20140 ILS-0.15 ILS-0.14 ILS
20130 ILS-0.16 ILS-0.17 ILS
20120 ILS-0.22 ILS-0.22 ILS
20110 ILS-0.21 ILS-0.2 ILS
20100 ILS-0.21 ILS-0.26 ILS
20090 ILS-0.13 ILS-0.17 ILS
20080 ILS-0.14 ILS-0.13 ILS
20070 ILS-0.25 ILS-0.22 ILS

BiondVax Pharmaceuticals business model

BiondVax Pharmaceuticals Ltd is an Israeli biopharmaceutical company specializing in the development and production of vaccines. The company was founded in 2003 and has since developed an innovative approach to preparing influenza vaccines. BiondVax's business model is focused on meeting the growing demand for vaccines while ensuring better efficacy and safety. The company uses the latest technologies and research methods to carefully examine the properties of viruses and develop tailor-made vaccines based on that information. BiondVax offers a wide range of products that focus on protecting against influenza viruses. The company's most important product is the M-001 vaccine, which has broad efficacy against various types of influenza viruses. This vaccine differs from conventional vaccines by independently stimulating and enhancing immunity, resulting in longer-lasting protection. The company is also developing other vaccines aimed at protecting against other infectious diseases such as herpes simplex or AIDS. A unique feature of BiondVax is the use of a targeted approach to cancer treatment, where the patient's immune system is specifically activated to kill cancer cells. BiondVax is a dynamic company that continuously invests in improving its technology and products. Since its founding, the company has made significant progress and achieved a number of milestones. For example, in 2017, the company received an important approval from the US Food and Drug Administration, allowing it to conduct a clinical trial process for its vaccine. BiondVax has also formed partnerships with other leading companies in the healthcare industry to support its research and development. Collaborating with companies such as Merck, Novartis, or the US Department of Defense allows BiondVax to further expand its business and develop more effective vaccines. Over the years, BiondVax has introduced numerous innovations in the industry. For example, the company has specialized in designing peptides, which are proteins that can serve as the basis for vaccines. The company has also utilized the latest technologies in immunology to make its vaccines even safer and more effective. Overall, BiondVax Pharmaceuticals Ltd has made impressive progress in recent years and has established itself as a leading company in the field of vaccine development. Through its innovative technologies and targeted approach to disease prevention, BiondVax is able to significantly impact the healthcare industry and serve a wider range of patients than before. BiondVax Pharmaceuticals is one of the most popular companies on Eulerpool.com.

BiondVax Pharmaceuticals SWOT Analysis

Strengths

BiondVax Pharmaceuticals Ltd possesses several strengths that contribute to their success:

  • Strong Research and Development Capabilities: BiondVax has a dedicated team of skilled researchers and scientists.
  • Advanced Technological Infrastructure: The company benefits from cutting-edge technological resources that enable efficient vaccine development processes.
  • Strategic Partnerships: BiondVax has established valuable partnerships with other pharmaceutical companies, leveraging their expertise and market access.
  • Global Presence: The company has a presence in multiple countries, allowing for broader market reach and international collaboration.

Weaknesses

Despite its strengths, BiondVax Pharmaceuticals Ltd also faces a few weaknesses:

  • Reliance on External Funding: The company heavily relies on external funding sources, which may pose financial challenges if funding becomes limited.
  • Product Development Risks: The development of vaccines carries inherent risks, such as clinical trial failures or regulatory hurdles, which can delay or hamper the commercialization process.
  • Dependency on Key Personnel: BiondVax's success is closely tied to the expertise and knowledge of key personnel. If key individuals leave or are unavailable, it may negatively impact the company's operations.

Opportunities

BiondVax Pharmaceuticals Ltd can seize the following opportunities:

  • Increasing Global Demand for Vaccines: With the growing emphasis on preventive healthcare, the demand for vaccines is expected to rise, providing a favorable market environment.
  • Expanding into Emerging Markets: BiondVax can explore opportunities in emerging markets, where the demand for vaccines is on the rise due to population growth and increasing healthcare awareness.
  • Strategic Collaborations: The company can enter into collaborations with renowned research institutions or pharmaceutical companies to enhance its R&D capabilities and accelerate product development.

Threats

BiondVax Pharmaceuticals Ltd should be mindful of the following threats:

  • Intense Competition: The pharmaceutical industry is highly competitive, with several established companies and new entrants. BiondVax needs to differentiate itself and stay ahead of competitors.
  • Regulatory Constraints: Compliance with stringent regulatory requirements can lengthen the time and costs associated with vaccine development and approval processes.
  • Pandemic Risks: While the COVID-19 pandemic has created opportunities for vaccine companies, unexpected outbreaks or viral mutations can pose challenges to vaccine development and commercialization efforts.

BiondVax Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

BiondVax Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

BiondVax Pharmaceuticals shares outstanding

The number of shares was BiondVax Pharmaceuticals in 2023 — This indicates how many shares 564.576 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BiondVax Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BiondVax Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BiondVax Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BiondVax Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BiondVax Pharmaceuticals Stock splits

In BiondVax Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for BiondVax Pharmaceuticals.

BiondVax Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
2.29464 % Angels Investments in Hi Tech, Ltd.427,404012/20/2022
1.18415 % Sabby Management, LLC220,562220,56212/31/2022
0.50317 % Daniel (Stone E)93,72193,7219/19/2022
0.09373 % Citadel Advisors LLC17,45917,45912/31/2022
0.01151 % Morgan Stanley & Co. LLC2,14356012/31/2022
0.00566 % Lowell (George H.)1,0541,05412/8/2022
0.00362 % Morgan Stanley Smith Barney LLC675-112/31/2022
0.00276 % Rotman (Avner)51451412/8/2022
0.00228 % CA Indosuez (Switzerland) S.A.424012/31/2022
0.00161 % UBS Financial Services, Inc.300-50512/31/2022
1
2
3
4
...
5

Most common questions regarding BiondVax Pharmaceuticals

What values and corporate philosophy does BiondVax Pharmaceuticals represent?

BiondVax Pharmaceuticals Ltd represents the values of innovation, research excellence, and commitment to public health. With a strong corporate philosophy focused on developing and commercializing innovative vaccines, BiondVax aims to improve the lives of individuals and communities worldwide. The company is dedicated to advancing preventative medicine through its unique proprietary technology platform, M-001, which aims to enhance the effectiveness of influenza vaccines. BiondVax Pharmaceuticals Ltd is committed to addressing global health challenges and contributing to the well-being of society through continuous scientific advancements and collaborations with healthcare professionals and organizations.

In which countries and regions is BiondVax Pharmaceuticals primarily present?

BiondVax Pharmaceuticals Ltd is primarily present in Israel.

What significant milestones has the company BiondVax Pharmaceuticals achieved?

BiondVax Pharmaceuticals Ltd has achieved several significant milestones in its growth and development. Notably, the company successfully completed a Phase 2b clinical trial for their flagship product, M-001, a universal flu vaccine that has shown promising results in providing broad protection against multiple influenza strains. BiondVax also secured funding and support from prestigious institutions, such as the European Union's Horizon 2020 program. Additionally, they have received regulatory approvals to commence Phase 3 trials, indicating the potential for commercialization in the near future. These achievements demonstrate BiondVax's dedication to innovative research and development, positioning them as a promising player in the pharmaceutical industry.

What is the history and background of the company BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals Ltd is a leading biopharmaceutical company focused on developing and commercializing innovative immunomodulation therapies for infectious diseases. Founded in 2003, the company is committed to improving global public health through its cutting-edge technologies. BiondVax's core product, M-001, is a universal flu vaccine designed to provide broad protection against multiple influenza strains. With a strong emphasis on research and development, the company has reached significant milestones, including successful clinical trials and collaborations with prestigious partners. BiondVax Pharmaceuticals Ltd is renowned in the healthcare industry for its dedication to advancing preventive medicine solutions and tackling global health challenges.

Who are the main competitors of BiondVax Pharmaceuticals in the market?

The main competitors of BiondVax Pharmaceuticals Ltd in the market are other pharmaceutical companies operating in the field of vaccine development and production. Some notable competitors include Pfizer, Moderna, Johnson & Johnson, Novavax, and Sanofi. These companies are engaged in research and development of vaccines for various diseases and viruses. BiondVax Pharmaceuticals Ltd faces stiff competition in its efforts to develop innovative and effective vaccines, with each competitor striving to offer their own unique solutions to public health challenges.

In which industries is BiondVax Pharmaceuticals primarily active?

BiondVax Pharmaceuticals Ltd primarily operates in the biopharmaceutical industry.

What is the business model of BiondVax Pharmaceuticals?

The business model of BiondVax Pharmaceuticals Ltd revolves around the development and commercialization of innovative vaccines for various viral diseases, with a particular focus on influenza. The company utilizes a proprietary technology platform, M-001, which enables the creation of a universal flu vaccine that offers broad protection against multiple strains and subtypes of the influenza virus. BiondVax Pharmaceuticals works towards conducting clinical trials, obtaining regulatory approvals, and partnering with global pharmaceutical companies for the distribution and marketing of its vaccines worldwide.

What is the P/E ratio of BiondVax Pharmaceuticals 2024?

The BiondVax Pharmaceuticals P/E ratio is -364.44.

What is the P/S ratio of BiondVax Pharmaceuticals 2024?

The BiondVax Pharmaceuticals P/S ratio is 0.

What is the AlleAktien quality score of BiondVax Pharmaceuticals?

The AlleAktien quality score for BiondVax Pharmaceuticals is 1/10.

What is the revenue of BiondVax Pharmaceuticals 2024?

The revenue cannot currently be calculated for BiondVax Pharmaceuticals.

How high is the profit of BiondVax Pharmaceuticals 2024?

The expected BiondVax Pharmaceuticals profit is -3.8 M ILS.

What is the business model of BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Ltd is a leading biopharmaceutical company specializing in the development and production of influenza vaccines. The company is headquartered in Jerusalem, Israel and operates subsidiaries in the USA and Europe. BiondVax Pharmaceuticals' business model focuses on innovative technologies and extensive research and development to meet the market demand for safe and effective influenza vaccines. The company works closely with leading scientific institutions and experts to develop cutting-edge solutions for influenza prevention. One of BiondVax Pharmaceuticals' key products is the Universal Flu Vaccine Candidate (M-001), a vaccine candidate that has the potential to significantly increase protection against seasonal and pandemic influenza viruses. M-001 is an innovative vaccine candidate based on peptide-based immune system stimulation technology, allowing for a broader range of influenza strains to be covered. In addition, BiondVax Pharmaceuticals also offers other products and services including the production of recombinant proteins, analysis of protein interactions, and protein design solutions. The company has extensive experience in the production, quality control, and scaling up of novel influenza vaccines. BiondVax Pharmaceuticals has also specialized in the development of technologies to enhance existing vaccines. This includes technological innovations aimed at improving the effectiveness of influenza vaccines in older adults and other high-risk groups. The company's technology is also intended to improve the duration and strength of immunity after vaccination. To realize its business model, BiondVax Pharmaceuticals has established an extensive research and development department. The company also collaborates closely with universities, research institutions, and other biotech companies to collectively develop new therapeutic solutions. The company also has a clear growth strategy. BiondVax Pharmaceuticals plans to expand into new geographic markets while also expanding its product range to meet the growing demand for vaccines and prophylactic treatments. In conclusion, BiondVax Pharmaceuticals Ltd is a leading biopharmaceutical company that focuses on the development and production of novel influenza vaccines. Through innovative technologies and extensive research and development, BiondVax Pharmaceuticals is able to deliver market-leading solutions that meet the demand for safe and effective vaccines. With a clear growth strategy and a strong commitment to research and development, BiondVax Pharmaceuticals will undoubtedly continue to make significant contributions to the healthcare industry in the coming years.

What is the BiondVax Pharmaceuticals dividend?

BiondVax Pharmaceuticals pays a dividend of 0 ILS distributed over payouts per year.

How often does BiondVax Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for BiondVax Pharmaceuticals or the company does not pay out a dividend.

What is the BiondVax Pharmaceuticals ISIN?

The ISIN of BiondVax Pharmaceuticals is US09073Q1058.

What is the BiondVax Pharmaceuticals WKN?

The WKN of BiondVax Pharmaceuticals is A14TFZ.

What is the BiondVax Pharmaceuticals ticker?

The ticker of BiondVax Pharmaceuticals is BVXV.

How much dividend does BiondVax Pharmaceuticals pay?

Over the past 12 months, BiondVax Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BiondVax Pharmaceuticals is expected to pay a dividend of 0 ILS.

What is the dividend yield of BiondVax Pharmaceuticals?

The current dividend yield of BiondVax Pharmaceuticals is .

When does BiondVax Pharmaceuticals pay dividends?

BiondVax Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of BiondVax Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is BiondVax Pharmaceuticals located?

BiondVax Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von BiondVax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BiondVax Pharmaceuticals from 9/30/2024 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did BiondVax Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of BiondVax Pharmaceuticals in the year 2023?

In the year 2023, BiondVax Pharmaceuticals distributed 0 ILS as dividends.

In which currency does BiondVax Pharmaceuticals pay out the dividend?

The dividends of BiondVax Pharmaceuticals are distributed in ILS.

All fundamentals about BiondVax Pharmaceuticals

Our stock analysis for BiondVax Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BiondVax Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.